Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism MAP3K13 inhibitors(mitogen-activated protein kinase kinase kinase 13 inhibitors), RIPK1 inhibitors(Receptor-interacting serine/threonine-protein kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Discovery | - | 01 Nov 2024 | |
Inflammation | Discovery | - | 01 Nov 2024 | |
Neoplasms | Discovery | - | 01 Nov 2024 | |
Neurodegenerative Diseases | Discovery | - | 01 Nov 2024 |